The proposed study is a multi-institutional historical chart review and longitudinal follow-up of identified patients with Wolman disease (WD) or Cholesteryl Ester Storage disease (CESD), lysosomal acid lipase deficiency (LAL). The overall goal of the proposed studies is to document and characterize the phenotypes, and their progression, as well as the determination of the genotypes of patients with lysosomal acid lipase (LAL; LPA locus) defects in the severe (WD) and attenuated (CESD) variants.
The specific aims are: 1. To characterize the degrees and progression of hepatic, splenic, intestinal, lung and adrenal involvement in CESD and WD using quantitative clinical assessments and to correlate these abnormalities with the genotype at the LPA locus. 2. To determine the variability of the phenotype in WD, a lethal infantile disease, and to quantify the rate of change of hepatic, splenic, intestinal malabsorptive and adrenal defects. These will be correlated with the genotype at the LPA locus. 3. Verify the impression that CSED and WD are non-CNS diseases and that CESD is significantly under diagnosed due to its marked variability with severely ill infants and nearly normal adults with 'fatty livers.' Correlations with mutation, biopsy (e.g.,liver), and serum cholesterol and triglyceride levels will be developed as historical controls for future ERT trials.
Wolman disease or Cholesteryl Ester Storage (CESD) disease patients will be studied to determine the natural history of liver, spleen, intestinal, lung and adrenal involvement, the relationship to their genotype, to verify that these diseases do not affect the central nervous system and to determine if CESD is underdiagnosed. This data will be essential for comparison for future enzyme replacement.
|Jarnes Utz, Jeanine R; Kim, Sarah; King, Kelly et al. (2017) Infantile gangliosidoses: Mapping a timeline of clinical changes. Mol Genet Metab 121:170-179|
|Whitley, Chester B (2017) WORLDSymposium™ 2017 Introduction. Mol Genet Metab 120:S2-S6|
|Ou, Li; Przybilla, Michael J; Koniar, Brenda et al. (2017) RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab :|
|Solomon, Melani; Muro, Silvia (2017) Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev 118:109-134|
|Mauer, Michael; Sokolovskiy, Alexey; Barth, Jay A et al. (2017) Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment. J Med Genet 54:781-786|
|Eisengart, Julie B; Jarnes, Jeanine; Ahmed, Alia et al. (2017) Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome. Mol Genet Metab Rep 13:64-68|
|Rairikar, Mugdha; Kazi, Zoheb B; Desai, Ankit et al. (2017) High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab 122:76-79|
|Ou, Li; Przybilla, Michael J; Whitley, Chester B (2017) Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis. Mol Genet Metab 120:101-110|
|Rairikar, Mugdha V; Case, Laura E; Bailey, Lauren A et al. (2017) Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G ""late-onset"" GAA variant. Mol Genet Metab 122:99-107|
|McIntosh, Paul T; Hobson-Webb, Lisa D; Kazi, Zoheb B et al. (2017) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab :|
Showing the most recent 10 out of 102 publications